MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.

When the former cohort of 1056 tumours was subdivided according to histology, we still observed a clear trend for worse prognosis in both common types of tumours, ADC and SCC (Fig. 2c ).

also in 19,460 other papers